{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:35:41Z","timestamp":1791887741938,"version":"4.3.4"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.biopha.2022.113324","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T18:05:09Z","timestamp":1656525909000},"page":"113324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":228,"special_numbering":"C","title":["Gene therapy clinical trials, where do we go? An overview"],"prefix":"10.1016","volume":"153","author":[{"given":"Fatemeh","family":"Arabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naser","family":"Ahmadbeigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113324_bib1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/hum.1990.1.4-371","article-title":"September 14, 1990: the beginning","volume":"1","author":"Anderson","year":"1990","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.biopha.2022.113324_bib2","series-title":"Elemente der exakten Erblichkeitslehre","author":"Johannsen","year":"1909"},{"key":"10.1016\/j.biopha.2022.113324_bib3","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1534\/genetics.116.196956","article-title":"The evolving definition of the term \u201cgene\u201d","volume":"205","author":"Portin","year":"2017","journal-title":"Genetics"},{"key":"10.1016\/j.biopha.2022.113324_bib4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/171737a0","article-title":"Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid","volume":"171","author":"Watson","year":"1953","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.113324_bib5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1089\/hum.1994.5.4-469","article-title":"An early history of gene transfer and therapy","volume":"5","author":"Wolff","year":"1994","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.biopha.2022.113324_bib6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1146\/annurev.bi.38.070169.002343","article-title":"DNA modification and restriction","volume":"38","author":"Arber","year":"1969","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.biopha.2022.113324_bib7","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1126\/science.186.4166.790","article-title":"DNA ligase: structure, mechanism, and function","volume":"186","author":"Lehman","year":"1974","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.113324_bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ng1092-93","article-title":"A brief history of gene therapy","volume":"2","author":"Friedmann","year":"1992","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2022.113324_bib9","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.8493530","article-title":"The basic science of gene therapy","volume":"260","author":"Mulligan","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.113324_bib10","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/310476a0","article-title":"Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse","volume":"310","author":"Williams","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.113324_bib11","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.1995.13.2.410","article-title":"Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin","volume":"13","author":"Merrouche","year":"1995","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2022.113324_bib12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.113324_bib13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/gt.2017.32","article-title":"New treatments for serious conditions: ethical implications","volume":"24","author":"King","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.biopha.2022.113324_bib14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease","volume":"288","author":"Cavazzana-Calvo","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.113324_bib15","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2022.113324_bib16","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2022.113324_bib17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The first approved gene therapy product for cancer Ad-p53 (gendicine): 12 years in the clinic","volume":"29","author":"Zhang","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.biopha.2022.113324_bib18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the world first oncolytic virus medicine and its update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.biopha.2022.113324_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(12)61992-8","article-title":"Europe gives gene therapy the green light","volume":"380","author":"Gruber","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113324_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/2155179018822781","article-title":"Approval of first CAR-Ts: have we solved all hurdles for ATMPs?","volume":"11","author":"Seimetz","year":"2019","journal-title":"Cell Med."},{"key":"10.1016\/j.biopha.2022.113324_bib21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/TACG.S230720","article-title":"Voretigene neparvovec and gene therapy for leber\u2019s congenital amaurosis: review of evidence to date","volume":"13","author":"Padhy","year":"2020","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.biopha.2022.113324_bib22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/ijabmr.IJABMR_190_19","article-title":"Onasemnogene abeparvovec for spinal muscular atrophy: the costlier drug ever","volume":"9","author":"Mahajan","year":"2019","journal-title":"Int. J. Appl. Basic Med. Res."},{"key":"10.1016\/j.biopha.2022.113324_bib23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113324_bib24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113324_bib25","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fgene.2019.00868","article-title":"Development and clinical translation of approved gene therapy products for genetic disorders","volume":"10","author":"Shahryari","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.biopha.2022.113324_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2019.107502","article-title":"The approved gene therapy drugs worldwide: from 1998 to 2019","volume":"40","author":"Ma","year":"2020","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.biopha.2022.113324_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-med-012017-043332","article-title":"Entering the modern era of gene therapy","volume":"70","author":"Anguela","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.biopha.2022.113324_bib28","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1093\/hmg\/ddz157","article-title":"Advances and challenges for hemophilia gene therapy","volume":"28","author":"Batty","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.biopha.2022.113324_bib29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biopha.2022.113324_bib30","first-page":"16849","article-title":"Suicide gene therapy for cancer - current strategies","volume":"4","author":"Zarogoulidis","year":"2013","journal-title":"J. Genet. Syndr. Gene Ther."},{"key":"10.1016\/j.biopha.2022.113324_bib31","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/intimm\/dxab013","article-title":"Development of COVID-19 vaccines utilizing gene therapy technology","volume":"33","author":"Nakagami","year":"2021","journal-title":"Int. Immunol."},{"key":"10.1016\/j.biopha.2022.113324_bib32","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2018-04-839217","article-title":"Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed\/refractory diffuse large B-cell lymphoma","volume":"132","author":"Chow","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.113324_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062114","article-title":"Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy","volume":"8","author":"Mitrpant","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.113324_bib34","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","article-title":"CRISPR gene therapy: applications, limitations, and implications for the future","volume":"10","author":"Uddin","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2022.113324_bib35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.biopha.2022.113324_bib36","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113324_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3015","article-title":"Gene therapy clinical trials worldwide to 2017: an update","volume":"20","author":"Ginn","year":"2018","journal-title":"J. Gene Med."},{"key":"10.1016\/j.biopha.2022.113324_bib38","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1038\/s41467-020-19505-2","article-title":"The once and future gene therapy","volume":"11","author":"Bulaklak","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2022.113324_bib39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/cgt.2016.82","article-title":"The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective","volume":"24","author":"Junghans","year":"2017","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.biopha.2022.113324_bib40","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-1-4939-8885-3_24","article-title":"Generation of CAR-T cells for cancer immunotherapy","volume":"1884","author":"Xu","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biopha.2022.113324_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111875","article-title":"Recent advances in regenerative medicine strategies for cancer treatment","volume":"141","author":"Mansouri","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2022.113324_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biopha.2022.113324_bib43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2022.113324_bib44","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2022.113324_bib45","article-title":"Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2022.113324_bib46","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/vaccines8040706","article-title":"DC-based vaccines for cancer immunotherapy","author":"Fu","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.biopha.2022.113324_bib47","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/21645515.2017.1412896","article-title":"Talimogene laherparepvec: first in class oncolytic virotherapy","volume":"14","author":"Conry","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.biopha.2022.113324_bib48","unstructured":"NHGR Institute, Genetic Disorders [cited 2022 6 July]. Available from: \u3008https:\/\/www.genome.gov\/For-Patients-and-Families\/Genetic-Disorders\u3009."},{"key":"10.1016\/j.biopha.2022.113324_bib49","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/bjp.2008.349","article-title":"Viral vectors: from virology to transgene expression","volume":"157","author":"Bouard","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113324_bib50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fonc.2019.00297","article-title":"Gene therapy leaves a vicious cycle","volume":"9","author":"Goswami","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2022.113324_bib51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1535676019899502","article-title":"Viral vector systems for gene therapy: a comprehensive literature review of progress and biosafety challenges","volume":"25","author":"Ghosh","year":"2020","journal-title":"Appl. Biosaf."},{"key":"10.1016\/j.biopha.2022.113324_bib52","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector-based vaccines","author":"Ura","year":"2014","journal-title":"Vaccines"},{"key":"10.1016\/j.biopha.2022.113324_bib53","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2022.113324_bib54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00005-010-0063-4","article-title":"Lentiviral vectors in gene therapy: their current status and future potential","volume":"58","author":"Escors","year":"2010","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.biopha.2022.113324_bib55","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3390\/v13081528","article-title":"Lentiviral vectors for T cell engineering: clinical applications, bioprocessing and future perspectives","volume":"13","author":"Labbe","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2022.113324_bib56","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3390\/cancers12051139","article-title":"Expanding the spectrum of adenoviral vectors for cancer therapy","author":"Gao","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2022.113324_bib57","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1002\/1873-3468.13691","article-title":"State-of-the-art human adenovirus vectorology for therapeutic approaches","volume":"593","author":"Gao","year":"2019","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2022.113324_bib58","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2022.113324_bib59","doi-asserted-by":"crossref","first-page":"7545","DOI":"10.3390\/ijms22147545","article-title":"How far are non-viral vectors to come of age and reach clinical translation in gene therapy?","volume":"22","author":"Sainz-Ramos","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.113324_bib60","doi-asserted-by":"crossref","first-page":"30675","DOI":"10.18632\/oncotarget.5169","article-title":"Progresses towards safe and efficient gene therapy vectors","volume":"6","author":"Chira","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2022.113324_bib61","first-page":"315","article-title":"An overview of the history, applications, advantages, disadvantages and prospects of gene therapy","volume":"30","author":"Jafarlou","year":"2016","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.biopha.2022.113324_bib62","first-page":"249","article-title":"Gene therapy, early promises, subsequent problems, and recent breakthroughs","volume":"3","author":"Razi Soofiyani","year":"2013","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.biopha.2022.113324_bib63","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/pgmj.2003.017764","article-title":"Gene therapy in clinical medicine","volume":"80","author":"Selkirk","year":"2004","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.biopha.2022.113324_bib64","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","article-title":"FDA-approved oligonucleotide therapies in 2017","volume":"25","author":"Stein","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2022.113324_bib65","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1089\/hum.2017.230","article-title":"Development of gene therapeutics for head and neck cancer in China: from bench to bedside","volume":"29","author":"Guo","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.biopha.2022.113324_bib66","series-title":"China Approves First Gene Therapy","author":"Pearson","year":"2004"},{"key":"10.1016\/j.biopha.2022.113324_bib67","first-page":"229","article-title":"The \u2018timely\u2019development of Rexin-G: first targeted injectable gene vector","volume":"35","author":"Gordon","year":"2009","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2022.113324_bib68","series-title":"Limb-Saving Medicines Sought to Prevent Amputations","author":"Willyard","year":"2012"},{"key":"10.1016\/j.biopha.2022.113324_bib69","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/mt.2012.194","article-title":"Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union","volume":"20","author":"Yl\u00e4-Herttuala","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2022.113324_bib70","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1158\/2159-8290.CD-NB2015-158","article-title":"First oncolytic viral therapy for melanoma","volume":"6","author":"Poh","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2022.113324_bib71","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1158\/1078-0432.CCR-15-2709","article-title":"Talimogene laherparepvec for the treatment of advanced melanoma","volume":"22","author":"Ott","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2022.113324_bib72","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fmed.2017.00053","article-title":"Advanced therapy medicinal products for rare diseases: state of play of incentives supporting development in Europe","volume":"4","author":"Farkas","year":"2017","journal-title":"Front. Med"},{"key":"10.1016\/j.biopha.2022.113324_bib73","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cell.2016.06.049","article-title":"Gene therapy for \u201cBubble Boy\u201d disease","volume":"166","author":"Hoggatt","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.113324_bib74","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/humc.2016.29010.ind","article-title":"Investor outlook: rising from the ashes; GSK\u2019s European Approval of Strimvelis for ADA-SCID","volume":"27","author":"Schimmer","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.biopha.2022.113324_bib75","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13023-018-0791-9","article-title":"Gene therapy in rare diseases: the benefits and challenges of developing a patient-centric registry for Strimvelis in ADA-SCID","volume":"13","author":"Stirnadel-Farrant","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.biopha.2022.113324_bib76","doi-asserted-by":"crossref","first-page":"737","DOI":"10.15252\/emmm.201707573","article-title":"Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products","volume":"9","author":"Aiuti","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.biopha.2022.113324_bib77","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/nat.2018.0756","article-title":"A sequel to the eteplirsen saga: eteplirsen is approved in the United States but was not approved in Europe","volume":"29","author":"Aartsma-Rus","year":"2019","journal-title":"Nucleic Acid. Ther."},{"key":"10.1016\/j.biopha.2022.113324_bib78","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/dmcn.14129","article-title":"A new era in the management of Duchenne muscular dystrophy","volume":"61","author":"Korinthenberg","year":"2019","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.biopha.2022.113324_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/tnsci-2017-0001","article-title":"ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy","volume":"8","author":"Ottesen","year":"2017","journal-title":"Transl. Neurosci."},{"key":"10.1016\/j.biopha.2022.113324_bib80","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1586\/17512433.2016.1172960","article-title":"Efficacy of rintatolimod in the treatment of chronic fatigue syndrome\/myalgic encephalomyelitis (CFS\/ME)","volume":"9","author":"Mitchell","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113324_bib81","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113324_bib82","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113324_bib83","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113324_bib84","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41584-018-0009-5","article-title":"Arthritis gene therapy is becoming a reality","volume":"14","author":"Evans","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.biopha.2022.113324_bib85","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.5435\/JAAOS-D-17-00695","article-title":"Arthritis gene therapy approved in Korea","volume":"26","author":"Evans","year":"2018","journal-title":"J. Am. Acad. Orthop. Surg."},{"key":"10.1016\/j.biopha.2022.113324_bib86","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/ph12020078","article-title":"Tegsedi (inotersen): an antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis","author":"Gales","year":"2019","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2022.113324_bib87","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1586\/14779072.2014.955850","article-title":"Beperminogene perplasmid for the treatment of critical limb ischemia","volume":"12","author":"Suda","year":"2014","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.biopha.2022.113324_bib88","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene abeparvovec: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2022.113324_bib89","unstructured":"E.M. Agency, Zynteglo [cited 2021 Nov 5]. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zynteglo\u3009."},{"key":"10.1016\/j.biopha.2022.113324_bib90","doi-asserted-by":"crossref","unstructured":"Y.A. Heo, Golodirsen: first approval, Drugs, 80, 2020, pp. 329\u2013333. \u300810.1007\/s40265-020-01267-2\u3009.","DOI":"10.1007\/s40265-020-01267-2"},{"key":"10.1016\/j.biopha.2022.113324_bib91","doi-asserted-by":"crossref","unstructured":"J. Paik, S. Duggan, Volanesorsen: first global approval, Drugs, 79, pp. 1349\u20131354. \u300810.1007\/s40265-019-01168-z\u3009.","DOI":"10.1007\/s40265-019-01168-z"},{"key":"10.1016\/j.biopha.2022.113324_bib92","unstructured":"FDA, FDA Approves Brexucabtagene Autoleucel for Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia [cited 2021 Nov 15]. Available from: \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic\u3009."},{"key":"10.1016\/j.biopha.2022.113324_bib93","unstructured":"E.M. Agency, Libmeldy. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/libmeldy\u3009."},{"key":"10.1016\/j.biopha.2022.113324_bib94","doi-asserted-by":"crossref","unstructured":"Y.N. Lamb, BNT162b2 mRNA COVID-19 vaccine: first approval, Drugs, 81, 2021, pp. 495\u2013501. \u300810.1007\/s40265-021-01480-7\u3009.","DOI":"10.1007\/s40265-021-01480-7"},{"key":"10.1016\/j.biopha.2022.113324_bib95","unstructured":"E.M. Agency, Spikevax (Previously COVID-19 Vaccine Moderna). Available from: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spikevax\u3009."},{"key":"10.1016\/j.biopha.2022.113324_bib96","doi-asserted-by":"crossref","unstructured":"L.J. Scott, Givosiran: first approval, Drugs, 80, 2020, pp. 335\u2013339. \u300810.1007\/s40265-020-01269-0\u3009.","DOI":"10.1007\/s40265-020-01269-0"},{"key":"10.1016\/j.biopha.2022.113324_bib97","doi-asserted-by":"crossref","unstructured":"L.J. Scott, S.J. Keam, Lumasiran: first approval, Drugs, 81, 2021, pp. 277\u2013282. \u300810.1007\/s40265-020-01463-0\u3009.","DOI":"10.1007\/s40265-020-01463-0"},{"key":"10.1016\/j.biopha.2022.113324_bib98","first-page":"235","article-title":"Pharmacological profile of viltolarsen for the treatment of duchenne muscular dystrophy: a Japanese experience","volume":"13","author":"Roshmi","year":"2021","journal-title":"Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113324_bib99","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.tips.2022.02.003","article-title":"siRNA drug Leqvio (inclisiran) to lower cholesterol","volume":"43","author":"Migliorati","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2022.113324_bib100","unstructured":"FDA, FDA Approves Lisocabtagene Maraleucel for Relapsed Or Refractory Large B-Cell Lymphoma [cited 2021 Nov 15]. Available from: \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-large-b-cell-lymphoma\u3009."},{"key":"10.1016\/j.biopha.2022.113324_bib101","unstructured":"FDA, FDA Approves Idecabtagene Vicleucel for Multiple Myeloma [cited 2021 Nov 15]. Available from: \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-idecabtagene-vicleucel-multiple-myeloma\u3009."},{"key":"10.1016\/j.biopha.2022.113324_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.828471","article-title":"Results of ARI-0001 CART19 cells in patients with chronic lymphocytic leukemia and Richter\u2019s transformation","volume":"12","author":"Ortiz-Maldonado","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2022.113324_bib103","unstructured":"Press Release Daiichi Sankyo Launches DELYTACT \u00ae Oncolytic Virus G47\u2206 in Japan. Available from: \u3008www.daiichisankyo.com\u3009."},{"key":"10.1016\/j.biopha.2022.113324_bib104","unstructured":"JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China. Available from: \u3008https:\/\/www.prnewswire.com\/in\/news-releases\/jw-therapeutics-announces-nmpa-approval-of-relmacabtagene-autoleucel-injection-in-china-837651458.html\u3009."},{"key":"10.1016\/j.biopha.2022.113324_bib105","unstructured":"FDA, FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation."},{"key":"10.1016\/j.biopha.2022.113324_bib106","unstructured":"E.M. Agency, Skysona."},{"key":"10.1016\/j.biopha.2022.113324_bib107","unstructured":"FDA, CARVYKTI [cited 2022 5 July]. Available from: \u3008https:\/\/www.fda.gov\/vaccines-blood-biologics\/carvykti\u3009."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222007132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222007132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T12:04:42Z","timestamp":1779969882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222007132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":107,"alternative-id":["S0753332222007132"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113324","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy clinical trials, where do we go? An overview","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113324","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113324"}}